Menu
Logo

OPSUMIT significantly reduced the risk of morbidity-mortality events compared to placebo in the primary analysis of all PAH patients in SERAPHIN

1_3.png


2_5.png

3_4.png


aAs measured by a composite primary endpoint. Results were driven by a decrease in PAH worsening and do not apply to
mortality on its own. bEvents defined as composite morbidity-mortality events.
PAH: Pulmonary arterial hypertension

TREATMENT WITH OPSUMIT IS ASSOCIATED WITH IMPROVED FUNCTIONAL CLASS STATUS WHEN COMPARED TO PLACEBO
Adapted from ref. 1

5_1.png


WHO: World Health Organization
REFERENCES:
1. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369 (9): 809-18.

2. OPSUMIT Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en
/documents/productinformation/opsumit-epar-product-information_en.pdf. Last accessed: November 28, 2019.

CP-250192

opsumit_footer.png